Skip to main content
. 2026 Sep 9;18(9):1133. doi: 10.3390/pharmaceutics18091133
SSRI Selective serotonin reuptake inhibitor
DDIs Drug–drug interactions
TDM Therapeutic drug monitoring
AGNP Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie
PK Pharmacokinetics
PGx Pharmacogenetics
ADRs Adverse drug reactions
C/D Concentration-to-dose ratio
MR Sertraline-to-norsertraline metabolic ratio
MRDN Metabolic ratio dose-normalized
LogMR Log10-transformed sertraline/norsertraline metabolic ratio
LogMRDN Log10-transformed dose-normalized sertraline/norsertraline metabolic ratio
BMI Body mass index
PCR Polymerase chain reaction
LLOQ Lower limit of quantification
BP Breusch–Pagan
gUM Genotype-predicted ultrarapid metabolizers
gIM Genotype-predicted intermediate metabolizers
gPM Genotype-predicted poor metabolizers
gNM Genotype-predicted normal metabolizers
gRM Genotype-predicted rapid metabolizers
CPIC Clinical Pharmacogenetics Implementation Consortium
DPWG Dutch Pharmacogenetics Working Group
ESI Electrospray ionization
ALT Alanine aminotransferase
AST Aspartate aminotransferase
GGT Gamma-glutamyl transferase
ALP Alkaline phosphatase
UGTs UDP-glucuronosyltransferases